Mar Vista Investment Partners LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 17.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 415,733 shares of the company’s stock after buying an additional 60,519 shares during the quarter. Johnson & Johnson accounts for about 2.9% of Mar Vista Investment Partners LLC’s portfolio, making the stock its 17th largest holding. Mar Vista Investment Partners LLC’s holdings in Johnson & Johnson were worth $64,439,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Waratah Capital Advisors Ltd. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at about $1,817,000. Robertson Stephens Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 9.8% in the 1st quarter. Robertson Stephens Wealth Management LLC now owns 26,170 shares of the company’s stock valued at $4,056,000 after buying an additional 2,327 shares during the period. Three Bridge Wealth Advisors LLC increased its stake in shares of Johnson & Johnson by 52.2% in the 1st quarter. Three Bridge Wealth Advisors LLC now owns 7,064 shares of the company’s stock valued at $1,095,000 after purchasing an additional 2,423 shares in the last quarter. Mount Yale Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 3.7% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 28,105 shares of the company’s stock valued at $4,356,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in shares of Johnson & Johnson by 1.8% in the 1st quarter. Commonwealth Equity Services LLC now owns 1,801,013 shares of the company’s stock valued at $279,157,000 after purchasing an additional 31,827 shares in the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.
Insiders Place Their Bets
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now directly owns 102,696 shares in the company, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock worth $7,928,856 over the last ninety days. Corporate insiders own 0.20% of the company’s stock.
Johnson & Johnson Trading Up 0.0 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same period in the prior year, the firm posted $2.59 earnings per share. The firm’s quarterly revenue was up 6.3% on a year-over-year basis. As a group, equities research analysts expect that Johnson & Johnson will post 10.75 EPS for the current year.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Wall Street Analyst Weigh In
JNJ has been the subject of several recent analyst reports. Stifel Nicolaus lifted their price target on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Credit Suisse Group lifted their price target on Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Raymond James boosted their price objective on Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research note on Monday, July 24th. Finally, JPMorgan Chase & Co. boosted their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Hold” and an average price target of $171.80.
Get Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Read More
- Five stocks we like better than Johnson & Johnson
- EV Stocks and How to Profit from Them
- 3 Inexpensive Mid Cap Tech Stocks With Good Growth Prospects
- How to Calculate Options Profits
- 3 Reasons the Dick’s Sporting Goods Selloff Is a Steal
- What Are MATANA Stocks?
- Foot Locker Stock Takes a Big Hit…Is It a Retail Bargain?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
